Pulmonary Hypertension: High Blood Pressure in the Lungs
We usually think of high blood pressure as a problem of the body's main circulation. But there's a separate, dangerous kind that affects only the blood vessels of the lungs — pulmonary hypertension — and it has its own specialised drugs that work by relaxing those lung vessels. Their mechanisms are a satisfying tour of vasodilation, with a familiar face from the erectile-dysfunction chapter.
The heart has two pumps. The left side pushes blood around the whole body — that's the circulation where ordinary high blood pressure (from the cardiovascular chapter) happens. The right side pushes blood through the lungs to pick up oxygen. Pulmonary hypertension is high blood pressure specifically in this lung circulation: the blood vessels of the lungs become narrowed and stiff, so the pressure inside them rises. This forces the right side of the heart to work much harder to push blood through, and over time that strain can cause the right heart to fail — a serious and life-limiting condition, causing breathlessness and fatigue. Because this is a distinct problem in a distinct set of vessels, it has its own distinct drugs, quite different from the ones used for ordinary hypertension.
The drug classes — all relax lung vessels
Three pathways, each opening up the narrowed pulmonary vessels. The specialised treatments for pulmonary arterial hypertension all share one goal: relax and widen the constricted lung blood vessels to lower the pressure. They do it through three main pathways, and one of them is a lovely callback. First, the endothelin receptor antagonists (the '-sentans', like bosentan) block endothelin, a powerful natural vessel-constrictor — take away the 'constrict' signal, and the vessels relax. Second, and here's the familiar face: the phosphodiesterase-5 (PDE5) inhibitors — sildenafil and tadalafil, the very same drugs from the erectile-dysfunction chapter — are used here too. They work through exactly the same nitric-oxide/cGMP pathway, boosting a natural vasodilator signal; it just happens that this pathway is prominent in the lung vessels, so the same drug that treats ED also relaxes the pulmonary circulation. Third, the prostacyclin pathway drugs (like epoprostenol and its analogues) supply or mimic prostacyclin, another potent natural vasodilator; these are powerful but often difficult to give (some need continuous intravenous infusion). A newer agent, riociguat, stimulates the same nitric-oxide pathway by a different mechanism. Different classes, one theme: open up the lung vessels to unload the struggling right heart.
Why it's a specialist area — and a key caution
Pulmonary hypertension is deliberately managed by specialists, and it's worth understanding why. First, it has several different causes — some cases arise on their own (idiopathic), while many others are secondary to another disease, most commonly long-standing lung disease like COPD, or left-sided heart failure. The treatment depends heavily on the cause: the powerful vessel-relaxing drugs above are mainly for the specific type called pulmonary arterial hypertension, and can actually be harmful if used in the wrong type (for example, aggressively dilating lung vessels when the real problem is a failing left heart can worsen things). So careful diagnosis comes first. Second, when pulmonary hypertension is caused by chronic lung disease, a cornerstone of management is simply treating that underlying disease well and, where appropriate, long-term oxygen (from the oxygen article) — because low oxygen itself constricts lung vessels. The practical message for most readers isn't to memorise these specialist drugs in detail, but to grasp the shape of the field: high pressure confined to the lung circulation, treated by relaxing the lung vessels through a few vasodilator pathways — including, memorably, the same sildenafil you met treating something quite different.
- Pulmonary hypertension = high blood pressure in the LUNG circulation, straining the right heart.
- Treatments relax the constricted lung vessels via three main pathways.
- Endothelin antagonists (-sentans, bosentan) block a vessel-constricting signal.
- PDE5 inhibitors (sildenafil/tadalafil) — the SAME ED drugs — work via the nitric-oxide/cGMP pathway.
- Prostacyclin drugs (epoprostenol) are potent vasodilators; treat the cause & use oxygen when lung disease drives it.
The delightful surprise in pulmonary hypertension is meeting sildenafil again. In the endocrine chapter it was a treatment for erectile dysfunction, working by boosting the nitric-oxide/cGMP pathway to relax blood vessels in one specific place. Here it turns up as a serious treatment for a serious lung condition — and it's the exact same drug, working by the exact same mechanism, just exploited in a different vascular bed. It's a beautiful illustration of a recurring truth in pharmacology: a drug isn't tied to one disease, it's tied to a mechanism, and wherever that mechanism is useful, the drug may find a role. The nitric-oxide/cGMP pathway relaxes vessels in the penis and in the lungs alike — so one molecule, understood by its mechanism, quietly serves two very different specialties.
- Treating all pulmonary hypertension the same — the drug choice depends heavily on the cause/type.
- Using potent pulmonary vasodilators when the cause is a failing left heart — can worsen it.
- Forgetting to treat the underlying lung disease and low oxygen driving secondary PH.
- Combining a PDE5 inhibitor with a nitrate — still dangerous here (severe hypotension).
Which drug from another chapter is also used to treat pulmonary hypertension?
- Pulmonary hypertension is high pressure in the lung circulation, straining the right heart.
- Drugs relax the lung vessels: endothelin antagonists (-sentans), PDE5 inhibitors (sildenafil), prostacyclins.
- It's specialist-managed and cause-dependent; treat underlying lung disease and give oxygen where relevant.
- Sildenafil (from the ED chapter) works here via the same nitric-oxide/cGMP pathway.
- Katzung BG. Basic & Clinical Pharmacology — Vasodilators & pulmonary hypertension.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Pulmonary arterial hypertension.
- ESC/ERS — Guidelines for the diagnosis and treatment of pulmonary hypertension.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Pulmonary vascular disease.
